

24th of September 2009



Save the date

Controversial Topics in Liver Transplantation

25 years with liver transplantation in Norway



RIKSHOSPITALET
– a part of Oslo University Hospital



Dear Colleague

You are hereby cordially invited to participate at the 25 Year Anniversary Symposium of liver transplantation in Norway. The symposium will take place at Oslo University Hospital, Rikshospitalet the 24th of September 2009 and will focus on three main topics:

- Liver transplantation for malignancy
- Split liver transplantation
- MARS treatment for liver failure

Norway has one transplant centre serving 4.7 mill people. Rikshospitalet has recently merged into Oslo University Hospital, the largest hospital trust in Scandinavia, employing nearly 30 000 people. The liver transplant program is steadily increasing, now exceeding 17 transplantations pmp. Oslo University Hospital has a strong tradition in frontline cancer research with The Norwegian Radium Hospital and recently the formation of Oslo Cancer Cluster. Due to a high rate of deceased donors we are in a position to explore liver transplantation for malignancy. This includes HCC patients beyond the Milan criteria, multimodal treatment and transplantation for cholangiocarcinoma and experimental liver transplantation for colo-rectal metastases. Do the results justify the use of liver grafts in these patients?

Increased use of split livers for transplantation could significantly boost the number of organs available and thus promote investigation of potential new indications for transplantation.

However, split liver transplantation is hampered with increased risk of postoperative complications. Is it worthwhile to refine split liver transplantation further, with the intention to improve outcome or will increased use of splits undermine the success of whole liver transplantation?

The Scandinavian collaboration of liver exchange for urgent patients is highly successful and very few patients die on the waiting list due to acute hepatic failure in the Nordic countries. Several extracorporeal systems for liver dialysis have been developed to facilitate liver recovery or act as bridge to transplantation. However, conclusive evidence of the benefit of MARS treatment has been difficult to achieve. Today's practice and how we should proceed regarding optimal treatment of liver failure is an important question for patients and for maximal utilization of deceased donor livers.

We are happy and honoured to host world leading professionals on the topics mentioned and are looking forward to fruitful discussions in order to promote further advances in the field of liver transplantation – Welcome to Oslo!



Aksel Foss
Head Liver Transplantation



Pål-Dag Line
Chair Division of Surgery

Controversial Topics in Liver Transplantation

25 years with liver transplantation in Norway

Present status and controversial topics

SESSION 1, 11.00–12.00

- 11.00 Welcome. *Aksel Foss*
- 11.10 Liver transplantation during 25 years in Norway. Adults: *Tim Scholz*. Children: *Truls Sanengen*
- 11.35 The Scandinavian cooperation in liver transplantation. *Krister Höckerstedt, Helsinki*
- 12.00 Coffee break

SESSION 2, 12.15–13.25 LIVER TRANSPLANTATION FOR MALIGNANCY

Chairman: Bo-Göran Ericzon, Stockholm

- 12.15 Introduction by chairman
- 12.25 Liver transplantation should be done more often for malignant diseases. *Pål-Dag Line, Oslo*
- 12.45 Liver transplantation should be limited in malignant diseases. *Ferdinand Mühlbacher, Vienna*
- 13.05 Discussion and conclusions
- 13.25 Lunch

SESSION 3, 14.25–15.30 SPLIT LIVER TRANSPLANTATION

Chairman: Michael Olausson, Gothenburg

- 14.25 Introduction by chairman
- 14.35 Split liver transplantation should be done more often. *Xavier Rogiers, Ghent*
- 14.55 Split liver transplantation should be limited. *James Neuberger, Birmingham*
- 15.15 Discussion and conclusion
- 15.35 Coffee break

SESSION 4, 15.50–17.00 MARS IN LIVER TRANSPLANTATION

Chairman: Lars Marius Ytrebø, Tromsø

- 15.50 Introduction by chairman
- 16.00 MARS should be used more often. *Helena Isoniemi, Helsinki*
- 16.20 The use of MARS should be limited. *William Bernal, London*
- 16.40 Discussion and conclusions
- 17.00 End of symposium
- 18.00 Anniversary dinner (optional)



NO REASON TO THINK TWICE

Registration at www.viaregi.se/oslolivertxmeeting

